Entera Bio Ltd.
ENTX Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2020โFY2025
Last close ยท Oct 23, 2026
$2.92
3.3%
Revenue
Total sales reported in the income statement.
$0.0M
76.8%
vs prior year
Operating margin
Operating income as a share of revenue.
โ27,450.0%
22,154.4ย pts
Net income
Profit after all expenses, interest and tax.
โ$11.4M
Free cash flow
Cash from operations minus capital spending.
โ$7.5M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
$147M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
8.6x
On $0.34 EPS (TTM)
What Entera Bio Ltd. does
No business description yet.
- Legal name
- Entera Bio Ltd.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Mar 27, 2026
- Accession ยท CIK
- 0001178913-26-001797
0001638097
Revenue and margins
Entera Bio Ltd. had $0.0M of revenue in fiscal 2025, down 76.8% on the year before.
FY20
Revenue $0.4M
FY21
Revenue $0.6M
FY22
Revenue $0.1M
FY23
Revenue $0.0M
FY24
Revenue $0.2M
FY25
Revenue $0.0M
Q3 '23
Revenue $0.0M
Q4 '23
Revenue $0.0M
Q1 '24
Revenue $0.0M
Q2 '24
Revenue $0.1M
Q3 '24
Revenue $0.0M
Q4 '24
Revenue $0.1M
Q1 '25
Revenue $0.0M
Q2 '25
Revenue $0.0M
Q3 '25
Revenue $0.0M
Q4 '25
Revenue $0.0M
Q1 '26
Revenue $0.0M
Q2 '26
Revenue $0.0M
FY20
Gross 17.8%
Operating โ3,059.7%
Net โ3,072.9%
FCF โ2,906.8%
FY21
Gross 34.7%
Operating โ2,139.6%
Net โ2,134.3%
FCF โ1,590.2%
FY22
Gross 24.6%
Operating โ9,714.2%
Net โ9,754.5%
FCF โ9,362.7%
FY23
Gross โ
Operating โ
Net โ
FCF โ
FY24
Gross 5.0%
Operating โ5,295.6%
Net โ5,271.3%
FCF โ3,768.5%
FY25
Gross 0.0%
Operating โ27,450.0%
Net โ27,235.7%
FCF โ17,802.4%
Gross
Operating
Net
FCF
Q3 '23
Gross โ
Operating โ
Net โ
FCF โ
Q4 '23
Gross โ
Operating โ
Net โ
FCF โ
Q1 '24
Gross โ
Operating โ
Net โ
FCF โ
Q2 '24
Gross 15.8%
Operating โ3,798.2%
Net โ3,763.2%
FCF โ2,342.1%
Q3 '24
Gross 0.0%
Operating โ7,192.9%
Net โ7,192.9%
FCF โ5,128.6%
Q4 '24
Gross 0.0%
Operating โ2,850.0%
Net โ2,875.6%
FCF โ1,792.7%
Q1 '25
Gross 0.0%
Operating โ6,102.4%
Net โ6,111.9%
FCF โ3,361.9%
Q2 '25
Gross โ
Operating โ
Net โ
FCF โ
Q3 '25
Gross โ
Operating โ
Net โ
FCF โ
Q4 '25
Gross โ
Operating โ
Net โ
FCF โ
Q1 '26
Gross โ
Operating โ
Net โ
FCF โ
Q2 '26
Gross โ
Operating โ
Net โ
FCF โ
Gross
Operating
Net
FCF
Net income and earnings per share
From fiscal 2020 to 2025, diluted EPS grew โ17.9% a year. Loss periods are shown in red.
FY20
Net income โ$11.2M
FY21
Net income โ$12.2M
FY22
Net income โ$13.1M
FY23
Net income โ$8.9M
FY24
Net income โ$9.5M
FY25
Net income โ$11.4M
Q3 '23
Net income โ$2.4M
Q4 '23
Net income โ$2.0M
Q1 '24
Net income โ$2.0M
Q2 '24
Net income โ$2.1M
Q3 '24
Net income โ$3.0M
Q4 '24
Net income โ$2.4M
Q1 '25
Net income โ$2.6M
Q2 '25
Net income โ$2.7M
Q3 '25
Net income โ$3.2M
Q4 '25
Net income โ$3.0M
Q1 '26
Net income โ$3.5M
Q2 '26
Net income โ$7.3M
FY20
Diluted EPS $0.67
FY21
Diluted EPS $0.47
FY22
Diluted EPS $0.45
FY23
Diluted EPS $0.31
FY24
Diluted EPS $0.25
FY25
Diluted EPS $0.25
Q3 '23
Diluted EPS $0.08
Q4 '23
Diluted EPS $0.07
Q1 '24
Diluted EPS $0.05
Q2 '24
Diluted EPS $0.06
Q3 '24
Diluted EPS $0.08
Q4 '24
Diluted EPS $0.06
Q1 '25
Diluted EPS $0.06
Q2 '25
Diluted EPS $0.06
Q3 '25
Diluted EPS $0.07
Q4 '25
Diluted EPS $0.06
Q1 '26
Diluted EPS $0.07
Q2 '26
Diluted EPS $0.14
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY20
Return on capital โ
Return on equity โ149.3%
Return on assets โ115.4%
FY21
Return on capital โ
Return on equity โ81.0%
Return on assets โ68.3%
FY22
Return on capital โ
Return on equity โ76.2%
Return on assets โ66.8%
FY23
Return on capital โ
Return on equity โ80.3%
Return on assets โ71.4%
FY24
Return on capital โ
Return on equity โ103.3%
Return on assets โ90.2%
FY25
Return on capital โ
Return on equity โ108.0%
Return on assets โ90.1%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ$7.5M in fiscal 2025, โ17,802.4% of revenue. Cash from operations minus capital spending.
FY20
Free cash flow โ$10.6M
FY21
Free cash flow โ$9.1M
FY22
Free cash flow โ$12.5M
FY23
Free cash flow โ$7.3M
FY24
Free cash flow โ$6.8M
FY25
Free cash flow โ$7.5M
Q3 '23
Free cash flow โ$1.5M
Q4 '23
Free cash flow โ$2.6M
Q1 '24
Free cash flow โ$1.9M
Q2 '24
Free cash flow โ$1.3M
Q3 '24
Free cash flow โ$2.2M
Q4 '24
Free cash flow โ$1.5M
Q1 '25
Free cash flow โ$1.4M
Q2 '25
Free cash flow โ$1.7M
Q3 '25
Free cash flow โ$2.5M
Q4 '25
Free cash flow โ$1.9M
Q1 '26
Free cash flow โ$3.1M
Q2 '26
Free cash flow โ$3.5M
FY20
Cash from operations โ$10.6M
Capital spending $0.1M
FY21
Cash from operations โ$9.1M
Capital spending $0.0M
FY22
Cash from operations โ$12.5M
Capital spending $0.0M
FY23
Cash from operations โ$7.3M
Capital spending $0.0M
FY24
Cash from operations โ$6.8M
Capital spending $0.0M
FY25
Cash from operations โ$7.4M
Capital spending $0.1M
Cash from operations
Capital spending
Q3 '23
Cash from operations โ$1.5M
Capital spending $0.0M
Q4 '23
Cash from operations โ$2.6M
Capital spending $0.0M
Q1 '24
Cash from operations โ$1.9M
Capital spending $0.0M
Q2 '24
Cash from operations โ$1.3M
Capital spending $0.0M
Q3 '24
Cash from operations โ$2.2M
Capital spending $0.0M
Q4 '24
Cash from operations โ$1.5M
Capital spending $0.0M
Q1 '25
Cash from operations โ$1.4M
Capital spending $0.0M
Q2 '25
Cash from operations โ$1.6M
Capital spending $0.0M
Q3 '25
Cash from operations โ$2.5M
Capital spending $0.0M
Q4 '25
Cash from operations โ$1.8M
Capital spending $0.0M
Q1 '26
Cash from operations โ$3.1M
Capital spending $0.0M
Q2 '26
Cash from operations โ$3.5M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
Entera Bio Ltd. returned โ to shareholders in fiscal 2025. The diluted share count rose 22.7%.
FY20
Dividends โ
Buybacks โ
FY21
Dividends โ
Buybacks โ
FY22
Dividends โ
Buybacks โ
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks โ
FY25
Dividends โ
Buybacks โ
Dividends
Buybacks
FY20
Diluted shares 0.02B
FY21
Diluted shares 0.03B
FY22
Diluted shares 0.03B
FY23
Diluted shares 0.03B
FY24
Diluted shares 0.04B
FY25
Diluted shares 0.05B
Balance sheet
Cash, debt and the ratios that show how comfortably Entera Bio Ltd. can carry it.
FY20
Cash $8.6M
Debt โ
FY21
Cash $24.9M
Debt โ
FY22
Cash $12.3M
Debt โ
FY23
Cash $11.0M
Debt โ
FY24
Cash $8.7M
Debt โ
FY25
Cash $7.1M
Debt โ
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $24.9M | $12.3M | $11.0M | $8.7M | $7.1M |
| Current ratio | 8.0x | 9.6x | 10.3x | 7.6x | 6.9x |
| Quick ratio | 8.0x | 9.6x | 10.3x | 7.6x | 6.9x |
| Total assets | $26.0M | $13.1M | $11.8M | $9.4M | $16.0M |
| Total liabilities | $3.4M | $1.4M | $1.4M | $1.3M | $2.9M |
| Shareholders' equity | $22.6M | $11.8M | $10.4M | $8.1M | $13.1M |
| Net debt (โ = net cash) | โ | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | 4 / 8 | 2 / 8 | 3 / 7 | 2 / 7 | 2 / 8 |
| Accruals ratio | โ6.8% | โ17.5% | โ2.9% | โ12.7% | โ25.7% | โ32.1% |
| Altman Z'' | โ22.80 | โ0.98 | โ15.64 | โ20.43 | โ34.49 | โ20.27 |
6 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $0.4M | $0.6M | $0.1M | $0.0M | $0.2M | $0.0M |
| Gross profit | $0.1M | $0.2M | $0.0M | $0.0M | $0.0M | $0.0M |
| Research and development | $6.4M | $6.8M | $5.8M | $4.5M | $4.5M | $6.0M |
| Operating income | โ$11.2M | โ$12.2M | โ$13.0M | โ$8.9M | โ$9.6M | โ$11.5M |
| Pretax income | โ$11.2M | โ$12.2M | โ$12.9M | โ$8.9M | โ$9.5M | โ$11.4M |
| Income tax | $0.0M | โ$0.1M | $0.1M | $0.0M | $0.0M | $0.0M |
| Net income | โ$11.2M | โ$12.2M | โ$13.1M | โ$8.9M | โ$9.5M | โ$11.4M |
| Diluted EPS | $0.67 | $0.47 | $0.45 | $0.31 | $0.25 | $0.25 |
| Diluted shares | 0.02B | 0.03B | 0.03B | 0.03B | 0.04B | 0.05B |
| Cash flow | ||||||
| Cash from operations | โ$10.6M | โ$9.1M | โ$12.5M | โ$7.3M | โ$6.8M | โ$7.4M |
| Capital expenditure | $0.1M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M |
| Free cash flow | โ$10.6M | โ$9.1M | โ$12.5M | โ$7.3M | โ$6.8M | โ$7.5M |
| Depreciation and amortization | $0.1M | $0.1M | $0.1M | $0.1M | $0.0M | $0.0M |
| Stock-based compensation | $0.9M | $1.9M | $2.2M | $1.7M | $2.6M | $2.8M |
| Balance sheet | ||||||
| Cash and short-term investments | $8.6M | $24.9M | $12.3M | $11.0M | $8.7M | $7.1M |
| Current assets | $9.1M | $25.3M | $12.8M | $11.3M | $9.0M | $15.3M |
| Current liabilities | $1.8M | $3.2M | $1.3M | $1.1M | $1.2M | $2.2M |
| Property and equipment, net | $0.2M | $0.2M | $0.1M | $0.1M | $0.1M | $0.1M |
| Total assets | $9.7M | $26.0M | $13.1M | $11.8M | $9.4M | $16.0M |
| Total liabilities | $2.2M | $3.4M | $1.4M | $1.4M | $1.3M | $2.9M |
| Shareholders' equity | $7.5M | $22.6M | $11.8M | $10.4M | $8.1M | $13.1M |
| Margins | ||||||
| Gross margin | 17.8% | 34.7% | 24.6% | โ | 5.0% | 0.0% |
| Operating margin | โ3,059.7% | โ2,139.6% | โ9,714.2% | โ | โ5,295.6% | โ27,450.0% |
| EBITDA margin | โ3,042.5% | โ2,130.3% | โ9,666.4% | โ | โ5,270.2% | โ27,378.6% |
| Net margin | โ3,072.9% | โ2,134.3% | โ9,754.5% | โ | โ5,271.3% | โ27,235.7% |
| FCF margin | โ2,906.8% | โ1,590.2% | โ9,362.7% | โ | โ3,768.5% | โ17,802.4% |
| Returns | ||||||
| Return on capital employed | โ141.7% | โ53.5% | โ110.4% | โ83.3% | โ116.7% | โ83.6% |
| Return on equity | โ149.3% | โ81.0% | โ76.2% | โ80.3% | โ103.3% | โ108.0% |
| Return on assets | โ115.4% | โ68.3% | โ66.8% | โ71.4% | โ90.2% | โ90.1% |
| Return on tangible equity | โ149.3% | โ54.0% | โ111.2% | โ85.6% | โ118.1% | โ87.3% |
| Growth | ||||||
| Revenue growth | โ | 56.4% | โ76.5% | โ100.0% | โ | โ76.8% |
| EPS growth | โ | โ29.9% | โ4.3% | โ31.1% | โ19.4% | 0.0% |
| Share count change | โ | 41.9% | 10.2% | 0.7% | 29.8% | 22.7% |
| Financial health | ||||||
| Current ratio | 4.9x | 8.0x | 9.6x | 10.3x | 7.6x | 6.9x |
| Quick ratio | 4.9x | 8.0x | 9.6x | 10.3x | 7.6x | 6.9x |
| Capital allocation | ||||||
| Capex / revenue | 14.5% | 3.0% | 35.1% | โ | 1.7% | 254.8% |
| Stock comp / revenue | 246.8% | 325.9% | 1,676.9% | โ | 1,412.2% | 6,547.6% |
| Quality scores | ||||||
| Piotroski F-score | โ | 4.0 | 2.0 | 3.0 | 2.0 | 2.0 |
| Altman Z'' | โ22.8 | โ1.0 | โ15.6 | โ20.4 | โ34.5 | โ20.3 |
| Accruals ratio | โ6.8% | โ17.5% | โ2.9% | โ12.7% | โ25.7% | โ32.1% |
Source: SEC EDGAR XBRL filings (CIK 0001638097). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.